Basic HIV Primary Care
You are just a few steps away from free CE credits!
Sign in or Register
A free account is required.
Study the Material
An entire Cc section, or just a few topics at a time.
Take the CE Quiz
5 questions covering the topics in each Cc section.
Claim CE Credit
Free CNE and Free CME available!
- Lesson 7 Overview
Substance Use Disorders - 0%Topic 1
BackgroundActivities- 0%Topic 2
Screening for Substance Use DisordersActivities- 0%Topic 3
Epidemiology of Substance Use in United StatesActivities- 0%Topic 4
Substance Use Disorders in People with HIVActivities- 0%Topic 5
Alcohol Use DisorderActivities- 0%Topic 6
Cannabis Use DisorderActivities- 0%Topic 7
Hallucinogen Use DisorderActivities- 0%Topic 8
Opioid Use DisorderActivities- 0%Topic 9
Stimulant Use DisorderActivities- 0%Topic 10
Tobacco Use DisorderSubstance Use Disorders Overview
About this Lesson
Last Updated: February 3rd, 2025CNE/CME Continuing Education
This lesson qualifies for:- 2 CME AMA PRA Category 1 Credits™, or
- 2 CNE contact hours and 2 CE contact hours (does NOT qualify for pharmacology CE for advanced practice nurses)
CNE and CME Origination: May 1st, 2017CNE and CME Review: September 1st, 2023CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
3Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled Substance Use Disorders and available until September 1st, 2023.Learning Objectives
- Discuss the resources available to screen for different substance use disorders
- Explore the epidemiology of substance use disorders in the United States
- Describe the unique impact that substance use disorders have on persons with HIV
- Explain the rationale for employing behavioral, psychosocial, and pharmacotherapy interventions in treating common substance use disorders
- Define the concept of harm reduction as related to treating substance use disorders
Lesson Contributors
Authors
Maria A. Corcorran, MD, MPHMaria A. Corcorran, MD, MPH
Assistant Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneJehan Z. Budak, MDJehan Z. Budak, MD
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneReviewers
David H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneLesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.
Requires sign-in for CE credit or Certificates
Funded byHealth Resources and Services Administration (HRSA)Created at University of WashingtonAn AETC ProgramPart of IDEA PlatformCME provided byUniversity of Alabama BirminghamCNE approved byOregon Nurses AssociationCopyright © 2025 National HIV CurriculumThe Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745 - 0%Topic 2
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant